{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:04:13Z","timestamp":1792263853423,"version":"4.4.0"},"reference-count":66,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T00:00:00Z","timestamp":1510617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068614"],"award-info":[{"award-number":["UM1 AI068614"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068635"],"award-info":[{"award-number":["UM1 AI068635"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068618"],"award-info":[{"award-number":["UM1 AI068618"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI069412"],"award-info":[{"award-number":["UM1 AI069412"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI069470"],"award-info":[{"award-number":["UM1 AI069470"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI069534"],"award-info":[{"award-number":["UM1 AI069534"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30 AI045008"],"award-info":[{"award-number":["P30 AI045008"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI069501"],"award-info":[{"award-number":["UM1 AI069501"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30 AI064518"],"award-info":[{"award-number":["P30 AI064518"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1002435","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T18:24:55Z","timestamp":1510683895000},"page":"e1002435","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":123,"title":["Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7460-733X","authenticated-orcid":true,"given":"Kenneth H.","family":"Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2009-3270","authenticated-orcid":true,"given":"Kelly E.","family":"Seaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunda","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2565-3879","authenticated-orcid":true,"given":"Nicole","family":"Grunenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8163-0714","authenticated-orcid":true,"given":"Mary","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Ledgerwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7824-0106","authenticated-orcid":true,"given":"Ian","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena E.","family":"Sobieszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9736-7957","authenticated-orcid":true,"given":"Benigno","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Van Tieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Bailer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8112-0853","authenticated-orcid":true,"given":"Barney S.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Mascola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-6319","authenticated-orcid":true,"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the HVTN 104 Protocol Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and the NIAID HIV Vaccine Trials Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"key":"ref1","unstructured":"UNAIDS DATA 2017, published 20 July 2017. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/20170720_Data_book_2017_en.pdf\" xlink:type=\"simple\">http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/20170720_Data_book_2017_en.pdf<\/ext-link>"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"MS Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"ref3","unstructured":"UNAIDS. Prevention gap report 2016 [January 14, 2017]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.unaids.org\/en\/resources\/campaigns\/prevention-gap\" xlink:type=\"simple\">http:\/\/www.unaids.org\/en\/resources\/campaigns\/prevention-gap<\/ext-link>."},{"issue":"23","key":"ref4","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMp1502020","article-title":"Ending the HIV-AIDS Pandemic\u2014Follow the Science","volume":"373","author":"AS Fauci","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"ref5","doi-asserted-by":"crossref","first-page":"12623","DOI":"10.1128\/JVI.01705-14","article-title":"Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies","volume":"88","author":"P Hraber","year":"2014","journal-title":"J Virol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-immunol-030409-101256","article-title":"The role of antibodies in HIV vaccines","volume":"28","author":"JR Mascola","year":"2010","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"e1005742","DOI":"10.1371\/journal.ppat.1005742","article-title":"Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization","volume":"12","author":"C Rademeyer","year":"2016","journal-title":"PLoS Pathog"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.it.2016.01.007","article-title":"HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies","volume":"37","author":"SW de Taeye","year":"2016","journal-title":"Trends Immunol"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nbt.2197","article-title":"B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study","volume":"30","author":"BF Haynes","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"6133","key":"ref10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"J Jardine","year":"2013","journal-title":"Science"},{"issue":"6244","key":"ref11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1126\/science.aac7800","article-title":"HIV. The modern era of HIV-1 vaccine development","volume":"349","author":"JR Mascola","year":"2015","journal-title":"Science"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1084\/jem.20122824","article-title":"Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies","volume":"210","author":"AT McGuire","year":"2013","journal-title":"J Exp Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design","volume":"34","author":"DR Burton","year":"2016","journal-title":"Annu Rev Immunol"},{"issue":"6151","key":"ref14","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1241144","article-title":"Antibodies in HIV-1 vaccine development and therapy","volume":"341","author":"F Klein","year":"2013","journal-title":"Science"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12075","article-title":"HIV-1 neutralizing antibodies: understanding nature&apos;s pathways","volume":"254","author":"JR Mascola","year":"2013","journal-title":"Immunol Rev"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","article-title":"Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth","volume":"45","author":"J Huang","year":"2016","journal-title":"Immunity"},{"issue":"17","key":"ref17","doi-asserted-by":"crossref","first-page":"8954","DOI":"10.1128\/JVI.00754-11","article-title":"Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01","volume":"85","author":"Y Li","year":"2011","journal-title":"J Virol"},{"issue":"5993","key":"ref18","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"X Wu","year":"2010","journal-title":"Science"},{"issue":"5993","key":"ref19","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"T Zhou","year":"2010","journal-title":"Science"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cell.2015.03.004","article-title":"Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection","volume":"161","author":"X Wu","year":"2015","journal-title":"Cell"},{"issue":"7524","key":"ref21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"SY Ko","year":"2014","journal-title":"Nature"},{"issue":"243","key":"ref22","doi-asserted-by":"crossref","first-page":"243ra88","DOI":"10.1126\/scitranslmed.3008992","article-title":"Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor","volume":"6","author":"A Pegu","year":"2014","journal-title":"Sci Transl Med"},{"issue":"21","key":"ref23","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo","volume":"88","author":"RS Rudicell","year":"2014","journal-title":"J Virol"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1128\/JVI.00210-15","article-title":"Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian\/Human Immunodeficiency Virus Infection","volume":"89","author":"KO Saunders","year":"2015","journal-title":"J Virol"},{"issue":"6049","key":"ref25","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"JF Scheid","year":"2011","journal-title":"Science"},{"issue":"30","key":"ref26","doi-asserted-by":"crossref","first-page":"E2083","DOI":"10.1073\/pnas.1208984109","article-title":"Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120","volume":"109","author":"AP West Jr.","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6049","key":"ref27","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1126\/science.1207532","article-title":"Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing","volume":"333","author":"X Wu","year":"2011","journal-title":"Science"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.immuni.2013.04.012","article-title":"Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies","volume":"39","author":"T Zhou","year":"2013","journal-title":"Immunity"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/00006454-200106000-00018","article-title":"Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group","volume":"20","author":"JR Groothuis","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMoa0907635","article-title":"Treatment with monoclonal antibodies against Clostridium difficile toxins","volume":"362","author":"I Lowy","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/ajt.12083","article-title":"Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study","volume":"13","author":"RT Chung","year":"2013","journal-title":"Am J Transplant"},{"issue":"Suppl 1","key":"ref32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2249.2009.04027.x","article-title":"Subcutaneous immunoglobulin: opportunities and outlook","volume":"158","author":"S Misbah","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults","volume":"182","author":"JE Ledgerwood","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"319","key":"ref34","doi-asserted-by":"crossref","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"RM Lynch","year":"2015","journal-title":"Sci Transl Med"},{"key":"ref35","first-page":"1","article-title":"Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults","volume":"2017","author":"Y Huang","journal-title":"MAbs"},{"key":"ref36","unstructured":"U.S. Department of Health and Human Services NIoH, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0. [Updated August 2009]. 2004."},{"key":"ref37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"DC Montefiori","year":"2009","journal-title":"Methods Mol Biol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","journal-title":"J Immunol Methods"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1128\/JVI.02853-13","article-title":"Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"88","author":"A deCamp","year":"2014","journal-title":"J Virol"},{"issue":"14","key":"ref40","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1128\/JVI.00171-11","article-title":"An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum","volume":"85","author":"G Ferrari","year":"2011","journal-title":"J Virol"},{"issue":"14","key":"ref41","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.1128\/JVI.00156-14","article-title":"HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities","volume":"88","author":"J Pollara","year":"2014","journal-title":"J Virol"},{"issue":"1\u20132","key":"ref42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","article-title":"A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples","volume":"366","author":"ME Ackerman","year":"2011","journal-title":"J Immunol Methods"},{"issue":"8","key":"ref43","doi-asserted-by":"crossref","first-page":"e1005817","DOI":"10.1371\/journal.ppat.1005817","article-title":"Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses","volume":"12","author":"MZ Tay","year":"2016","journal-title":"PLoS Pathog"},{"issue":"2","key":"ref44","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.virol.2006.04.043","article-title":"A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses","volume":"353","author":"HX Liao","year":"2006","journal-title":"Virology"},{"issue":"2","key":"ref45","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/JVI.70.2.1100-1108.1996","article-title":"Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1","volume":"70","author":"A Trkola","year":"1996","journal-title":"J Virol"},{"issue":"5","key":"ref46","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"S Johnson","year":"1997","journal-title":"J Infect Dis"},{"issue":"34","key":"ref47","doi-asserted-by":"crossref","first-page":"14216","DOI":"10.1073\/pnas.1111497108","article-title":"Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin","volume":"108","author":"JR Whittle","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"ref48","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1128\/JVI.03765-13","article-title":"Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity","volume":"88","author":"P Liu","year":"2014","journal-title":"J Virol"},{"issue":"14","key":"ref49","doi-asserted-by":"crossref","first-page":"7828","DOI":"10.1128\/JVI.02737-12","article-title":"Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees","volume":"87","author":"P Liu","year":"2013","journal-title":"J Virol"},{"key":"ref50","article-title":"R: A Language and Environment for Statistical Computing","year":"2012"},{"issue":"3","key":"ref51","doi-asserted-by":"crossref","first-page":"e1005520","DOI":"10.1371\/journal.ppat.1005520","article-title":"Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection","volume":"12","author":"K Wagh","year":"2016","journal-title":"PLoS Pathog"},{"issue":"6362","key":"ref52","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/355728a0","article-title":"Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody","volume":"355","author":"EA Emini","year":"1992","journal-title":"Nature"},{"issue":"12","key":"ref53","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1086\/420833","article-title":"Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies","volume":"189","author":"F Ferrantelli","year":"2004","journal-title":"J Infect Dis"},{"issue":"8","key":"ref54","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nm.1974","article-title":"Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques","volume":"15","author":"AJ Hessell","year":"2009","journal-title":"Nat Med"},{"issue":"5","key":"ref55","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1128\/JVI.73.5.4009-4018.1999","article-title":"Protection of Macaques against pathogenic simian\/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies","volume":"73","author":"JR Mascola","year":"1999","journal-title":"J Virol"},{"issue":"10","key":"ref56","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.1128\/JVI.71.10.7198-7206.1997","article-title":"Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12","volume":"71","author":"JR Mascola","year":"1997","journal-title":"J Virol"},{"issue":"2","key":"ref57","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/72318","article-title":"Protection of macaques against vaginal transmission of a pathogenic HIV-1\/SIV chimeric virus by passive infusion of neutralizing antibodies","volume":"6","author":"JR Mascola","year":"2000","journal-title":"Nat Med"},{"issue":"17","key":"ref58","doi-asserted-by":"crossref","first-page":"8340","DOI":"10.1128\/JVI.75.17.8340-8347.2001","article-title":"Antibody protects macaques against vaginal challenge with a pathogenic R5 simian\/human immunodeficiency virus at serum levels giving complete neutralization in vitro","volume":"75","author":"PW Parren","year":"2001","journal-title":"J Virol"},{"issue":"2","key":"ref59","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/5568","article-title":"Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1\/SIV chimeric virus infections of macaque monkeys","volume":"5","author":"R Shibata","year":"1999","journal-title":"Nat Med"},{"issue":"1","key":"ref60","doi-asserted-by":"crossref","DOI":"10.1515\/scid-2016-0001","article-title":"Basis and statistical design of the passive HIV-1 antibody mediated prevention (AMP) test-of-concept efficacy trials","volume":"9","author":"P Gilbert","year":"2017","journal-title":"Statistical Communications in Infectious Diseases"},{"issue":"4","key":"ref61","doi-asserted-by":"crossref","first-page":"e1001616","DOI":"10.1371\/journal.pmed.1001616","article-title":"HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission","volume":"11","author":"Y Voronin","year":"2014","journal-title":"PLoS Med"},{"issue":"6","key":"ref62","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"S Bournazos","year":"2014","journal-title":"Cell"},{"issue":"7601","key":"ref63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature17677","article-title":"A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges","volume":"533","author":"R Gautam","year":"2016","journal-title":"Nature"},{"issue":"5","key":"ref64","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1128\/JVI.03136-14","article-title":"Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes","volume":"89","author":"R Kong","year":"2015","journal-title":"J Virol"},{"issue":"7","key":"ref65","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.cell.2016.04.050","article-title":"Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency","volume":"165","author":"S Bournazos","year":"2016","journal-title":"Cell"},{"issue":"7","key":"ref66","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.cell.2016.05.024","article-title":"Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity","volume":"165","author":"Y Huang","year":"2016","journal-title":"Cell"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1002435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T20:57:48Z","timestamp":1603313868000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1002435"}},"subtitle":[],"editor":[{"given":"Linda-Gail","family":"Bekker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":66,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1002435","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,14]]}}}